UNSPSC 51161539: Etamiphyllin or etamiphylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C13H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 221A91BQ2S, chemically known as 1,3-dimethyl-7-(2-(diethylamino)ethyl)xanthine but generally known as etamiphyllin, which bears US NIH Compound Identifier 28329. European Medicines Agency schedules Etamiphyllin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13725MIG.

UNSPSC 51161539 Etamiphyllin or etamiphylline is a Commodity code covering pharmaceutical active ingredients and finished drug products supplied to state and local health care and correctional facilities. Recent state and local procurement under this code solicits manufacturers of generic and over-the-counter pharmaceuticals to supply finished products through authorized wholesaler networks under multi-year cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body in recent activity, using cooperative purchasing vehicles to aggregate demand across participating state and local government members in multiple states. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), and carry comprehensive insurance including workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Evaluations weight price competitiveness at 75 percent, with fixed pricing, compliance with administrative fee data formats, electronic data interchange capability, and agreement to a 3 percent administrative fee accounting for the remaining 25 percent.

MMCAP's most recent RFP (S1070000015802), posted January 20, 2026, with proposals due March 26, 2026, establishes multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Minnesota and Oregon. Products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. The contract term is two years for new responders with optional extensions at MMCAP's sole discretion, while incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Vendors should expect to pay a 3 percent administrative fee on all contract purchases and comply with performance penalties ranging from $200 to $1,500 per violation. The RFP does not disclose specific award values or budget ranges, and the solicitation does not identify set-aside designations or restrictions limiting responses to particular business classifications.